ICON’s novel RNA-based NGS assay, Dup-Seq BCR::ABL1, represents a significant advancement in the management of CML patients.

More than $994 million has been raised by Cambridge technology companies in the past 12 months (to October 16, 2024) – helped ...

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

The S&P/ASX 200 Information Technology sector fell 4.43% in October but leads ASX sectors YTD, up 41.95% Global X investment ...

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

The "Chronic Myeloid Leukemia (CML) in the United States: Quality of Life & Information-Seeking Behaviors" report has been added to ResearchAndMarkets.com's offering.This report provides a ...

Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.

Their work can help to lower the ... The Evolution of Green Energy Technology: Developing Three-Dimensional Smart Energy Devices With Radiant Cooling and Solar Absorption Oct. 25, 2024 — - DGIST ...

Commissions do not affect our editors' opinions or evaluations. Over the past 10 years, the technology sector has enjoyed stratospheric performance. You can’t even match the tech funds category ...

Chase Mining Corporation Limited (AU:GCM) has released an update. Chase Mining Corporation Limited has acquired an innovative technology to ...

Join the CML Book Club! The CTV Morning Live hosts will share a new title each month. Read along, share your thoughts, and recommend your favourite books. The CML Book Club’s first selection is ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...